Armata Pharmaceuticals (ARMP) Non-Current Debt (2023 - 2026)
Armata Pharmaceuticals (ARMP) posted Non-Current Debt of $88.0 million for Q1 2026, down 14.64% sequentially from $103.1 million in Q4 2025.
Armata Pharmaceuticals (ARMP) Non-Current Debt (2023 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Non-Current Debt for 4 years, with the latest figure at $88.0 million in Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.0 million (changed N/A YoY) and the FY2025 annual result came in at $103.1 million, up 357.26% from the prior year.
- Non-Current Debt eased to $88.0 million in Q1 2026 per ARMP's latest filing, from $103.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $103.1 million in Q4 2025 and troughed at $15.2 million in Q3 2025.
- A 4-year average of $44.3 million and a median of $23.7 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt declined 4.79% in 2024, then jumped 357.26% in 2025.
- Over 4 years, Non-Current Debt stood at $23.7 million in 2023, then retreated by 4.79% to $22.5 million in 2024, then surged by 357.26% to $103.1 million in 2025, then declined by 14.64% to $88.0 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $88.0 million, $103.1 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 8.96 Bn |
| 10 | Armata Pharmaceuticals | 172.13 Mn | 148.13 Mn | - | 42.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.02 Mn |
| Mar 31, 2026 | 87.98 Mn |
| Dec 31, 2025 | 103.06 Mn |
| Sep 30, 2025 | 15.24 Mn |
| Dec 31, 2024 | 22.54 Mn |
| Mar 31, 2024 | 35.37 Mn |
| Dec 31, 2023 | 23.67 Mn |
| Sep 30, 2023 | 22.28 Mn |